European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading

MT Newswires Live06-03

European equities traded in the US as American depositary receipts fell in Monday trading, declining 0.53% to 1,420.98 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical companies DBV Technologies (DBVT) and Genfit (GNFT), which rose 6.9% and 6.8% respectively. They were followed by biopharmaceutical company Grifols (GRFS) and biotech firm BioNTech (BNTX), which were up 3.4% and 2.8% respectively.

The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and semiconductor company Sequans Communications (SQNS), which dropped 6.6% and 5.2% respectively. They were followed by biotech firm Evaxion Biotech (EVAX) and oil and gas company TotalEnergies (TTE), which fell 2.7% and 1.9% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals (BDRX) and Bicycle Therapeutics (BCYC), which climbed 8.9% and 6% respectively. They were followed by biotech firm Trinity Biotech (TRIB) and biopharmaceutical company Verona Pharma (VRNA), which increased 4.5% and 3.6% respectively.

The decliners from the UK and Ireland were led by pharmaceutical company GSK (GSK) and biopharmaceutical company Akari Therapeutics (AKTX), which lost 8.1% each. They were followed by construction materials supplier CRH (CRH) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which were down 3.1% and 1.8% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment